Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG

Othus, M. et al. (2023) Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG. Leukemia and Lymphoma, 64(1), pp. 250-252. (doi: 10.1080/10428194.2022.2131416) (PMID:36226777)

Full text not currently available from Enlighten.

Abstract

No abstract available.

Item Type:Articles (Letter)
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Burnett, Professor Alan
Authors: Othus, M., Thomas, I., Wang, X., Ariti, C., Mehta, P., Sydenham, M., Hills, R. K., Burnett, A. K., Nand, S., Assouline, S., Michaelis, L. C., Erba, H. P., Russell, N., Kerr, K. F., Walter, R. B., and Dennis, M.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Leukemia and Lymphoma
Publisher:Taylor & Francis
ISSN:1042-8194
ISSN (Online):1029-2403
Published Online:13 October 2022

University Staff: Request a correction | Enlighten Editors: Update this record